(9Z,12Z)-N-[2-[2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]ethyldisulfanyl]ethyl]octadeca-9,12-dienamide | 765922-91-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (9Z,12Z)-N-[2-[2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]ethyldisulfanyl]ethyl]octadeca-9,12-dienamide
• CAS: 765922-91-6
• 化学式: C₄₀H₇₂N₂O₂S₂
• 分子量: 677.156
• InChiKey: PLGHNGDJOMSEEW-MAZCIEHSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.23
• 重原子数：
  46.0
• 可旋转键数：
  35.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  58.2
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  胱胺 、 (Z,Z)-9,12-十八烷二烯酸二聚物 生成 (9Z,12Z)-N-[2-[2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]ethyldisulfanyl]ethyl]octadeca-9,12-dienamide
  参考文献：
  名称：

  ARAI, DZYUNITIRO;KUMONAKA, KEXIRO;VASIBAYASI, TOSIO

  摘要：

  DOI：

文献信息

• A potential new prodrug for the treatment of cystinosis: Design, synthesis and in-vitro evaluation
  作者：Bridgeen McCaughan、Graeme Kay、Rachel M. Knott、Donald Cairns

  DOI：10.1016/j.bmcl.2008.01.039

  日期：2008.3

  Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in the cells of most organs. The disorder is treated by regular administration of the aminothiol, cysteamine, an odiferous and unpleasant tasting compound that along with its metabolites is excreted in breath and sweat, leading to poor patient compliance. In an attempt to improve patient compliance a series of novel prodrugs has been designed and evaluated as a potential new treatment for nephropathic cystinosis. The first of the prodrugs tested, 3a, was found to decrease the levels of intracellular cystine in cystinotic fibroblasts. This is the first report of a potential new therapeutic treatment for nephropathic cystinosis since the advent of cysteamine bitartrate. (C) 2008 Elsevier Ltd. All rights reserved.